by Moleculin Biotech (MBRX) has announced that the Canadian Intellectual Property Office, CIPO, has issued a notification of allowance for patent application no. 3.142.510 entitled: “Preparation of preliposomal Annamycin Lyophilate.” A patent of the application is expected to be issued in the coming months. Wanneer uitgegeven, zullen de patentclaims betrekking hebben op methoden voor het maken van een preliposomale Annamycin -lyofilizaat met verbeterde stabiliteit en hoge zuiverheid, met een basispatentterm die zich momenteel uitstrekt tot juni 2040, onder voorbehoud van verlenging om te verklaren dat de tijd nodig is om te voldoen aan de vereisten om te voldoen aan de vereisten voor wettelijke goedkeuring. Moleculin’s new drug candidate is positioned to become the very first non-cardiotoxic anthracycline ever that is approved and is currently being developed for the treatment of acute myeloid leukemia and sarcoma lung metastases for soft tissue.
-
Take advantage of Tipranks Premium with a 55% discount! Unlocking powerful investment tools, advanced data and expert analyst insights to help you invest with trust.
First published on Fleece -The ultimate source for real -time, market -moving breaking of financial news. Try it now >>
See the top stocks Recommended by Analysts >>
Read more about MBRX:
Disclaimer & DisclosurerePort a problem
